In its round-up of the of the International Conference on Family Planning Kigali, Rwanda, Devex cited two of the Council’s contraceptive innovations as major highlights of the 2018 conference.
At The Conversation, Council researcher Karen Austrian discussed how the Adolescent Girls Initiative-Kenya (AGI-K) program is reaching vulnerable girls in urban and rural communities who are at risk of dropping out of school, sexual violence and early sexual initiation, early and unintended pregnancy, and early marriage.
In a video interview, Judith Bruce explains that financial concerns can take much of the sentimentality and romance out of marriage.
In a timely op-ed at Project Syndicate, Thoai Ngo, Director of the GIRL Center, argues that researchers, programmers, and donors should embrace open data as a critical tool to promote sound investments and ensure efforts to improve girls’ lives are informed by evidence, not intuition.
Without investing in women’s sexual and reproductive health and rights, the world cannot drive societal progress to achieve the Sustainable Development goals, argues Zeba Sathar, Pakistan Country Director for the Population Council and Marleen Temmerman, Director of the Center of Excellence in Women and Child Health and Chair of the Department of Obstetrics and Gynaecology at the Aga Khan University.
In a blog post at the Maternal Health Task Force, Ann Blanc, Vice President of Social and Behavioral Science Research at the Population Council, makes a powerful case for why investing in high-quality research matters, now more than ever.
In a blog post for FHI 360’s Contraceptive Technology Innovation Exchange, Julia Bunting, President of the Population Council, and Laneta Dorflinger, Distinguished Scientist and Director for Contraceptive Technology, outline what needs to be done to increase access to the broadest choice of quality, affordable, and acceptable contraceptives.
This summer, the Population Council's Nestorone®/Testosterone transdermal gel, a new topical gel that blocks sperm production, will begin a Phase IIb clinical trial. The trial will start in the U.S. before being expanded to Britain, Italy, Sweden, Chile, and Kenya.
Council researcher Nanlesta Pilgrim writes about the U.S. Food and Drug Administration (FDA)'s recent decision to expand the approval of Truvada as pre-exposure prophylaxis (PrEP) against HIV for use in at-risk adolescents and the continued need to improve services for adolescents, in the U.S. and around the world.
In a blog post for FHI 360’s Contraceptive Technology Innovation Exchange, the Council’s Saumya RamaRao, senior associate, and Loreley Villamide-Herrera, biomedical program manager, highlight the latest advances in the novel drug delivery platform of vaginal rings.
